Cipla reported INR167.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Arca Biopharma USD 4.6M 4.1M Mar/2026
aTyr Pharma 59.81M 10.02M Sep/2026
Bio Path 677K 547K Mar/2026
Capricor Therapeutics 3.05M 2.46M Dec/2025
Cara Therapeutics 23.53M 113.18M Sep/2026
Cipla INR 167.4M 2.9M Sep/2026
Dr.Reddys Laboratories INR 1.26B 198M Jun/2026
Immunic 197K 222K Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sun Pharmaceuticals INR 859M 139.6M Mar/2026
TherapeuticsMD USD 20K 25K Sep/2023
UPL INR 8.19B 170M Sep/2026